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Edited by Bernd HelmsAbstract Trypanosomes are unicellular parasites and like all
decent parasites, they try to obtain from the host as much mate-
rial as possible, including lipids. However, the needs of a parasite
are not always the same as those of the host, and therefore,
mostly, some biosynthetic work still has to be done by the para-
site itself. Very often at least modiﬁcations of the lipid compo-
nents that are acquired from the host have to be made.
Furthermore, next to the lipids Trypanosoma brucei indeed ob-
tains from the host, some other lipid components have to be syn-
thesized de novo. Especially the processes where the metabolism
of T. brucei diﬀers from that of the host, will be discussed, as at
least some of them are excellent targets for the development of
urgently needed new chemotherapeutics.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Trypanosoma brucei is a unicellular eukaryote that causes
sleeping sickness in humans and nagana in livestock. T. brucei
threatens 60 million people in sub-Saharan Africa and approx-
imately 400000 cases are estimated to occur each year. More-
over, animal trypanosomiasis is one of the major constraints to
livestock production in sub-Saharan Africa. African trypano-
somes are not only of scientiﬁc interest because of their clinical
and veterinary interest, but also because these protozoa pos-
sess a number of unusual biological features [1].
T. brucei lives exclusively as an extra-cellular parasite unlike
some other members of the family of Trypanosomatidae, such
as Trypanosoma cruzi and Leishmania species, which possess
intra-cellular stages. T. brucei parasites undergo a complex life
cycle through the bloodstream of their mammalian host and
the blood-feeding insect vector, the tsetse ﬂy (Glossina spp.).Abbreviations: DHAP, dihydroxy-acetonephosphate; GPI, glycosyl-
phosphatidylinositol; HMG-CoA, 3- hydroxy-3-methylglutaryl coen-
zyme A; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG,
phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylser-
ine; VSG, variant surface glycoprotein
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doi:10.1016/j.febslet.2006.07.056During their life cycle, trypanosomes encounter many diﬀerent
environments and respond to these by dramatic morphological
and metabolic changes, including adaptation of their lipid and
energy metabolism. Trypanosomatidae are unusual with re-
spect to the subcellular compartmentation of their energy
metabolism, because a large part of the glycolytic pathway is
sequestered within peroxisome-like organelles, called glyco-
somes [2]. The long-slender form that lives in the bloodstream
of its mammalian host has a very simple type of energy metab-
olism, as it is entirely dependent on degradation of glucose to
pyruvate by glycolysis [3]. On the other hand, in the procyclic
form living in the insect midgut, the energy metabolism is
changed drastically. Mitochondrial metabolism is now more
pronounced and, next to glucose, amino acids are substrates
for the production of ATP (reviewed in: [4,5]). Furthermore,
in this stage of the life cycle, parts of the Krebs cycle are active
and used for catabolic as well as anabolic purposes [6]. There
are also large diﬀerences in lipid metabolism between the
bloodstream and procyclic forms of T. brucei.
Lipids play a variety of important roles in life. They are an
important form of stored energy in many organisms and the
major constituents of biomembranes. Speciﬁc lipids serve as
cofactors, detergents, transporters, hormones, extracellular
and intracellular messengers, pigments and anchors for mem-
brane proteins. As the lipid metabolism of T. brucei diﬀers in
many respects from that of its mammalian host, it oﬀers poten-
tial and promising targets for the development of urgently
needed, new chemotherapeutic drugs to combat these para-
sites.2. Fatty acid degradation for the generation of ATP
In many organisms the oxidation of fatty acids is an impor-
tant source of ATP. This is, however, not the case in most par-
asites [7] and bloodstream and procyclic forms of T. brucei are
no exception (see below). In principle T. brucei should be able
to perform b-oxidation, because homologues of genes for the
four enzymes in b-oxidation of acyl-CoA moieties are present
in its genome [8]. In animal cells the mitochondrial matrix is
the major site for b-oxidation of fatty acids, but in plant cells
b-oxidation occurs predominantly in the peroxisomes of the
leaves and in the glyoxysomes of the germinating seeds. Apart
from a mitochondrion, trypanosomes contain also glycosomes,
peroxisomal-like organelles where the ﬁrst seven reactions of
glycolysis occur. In the Tritryps genome analysis it wasblished by Elsevier B.V. All rights reserved.
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acids via b-oxidation in two separate compartments: glyco-
somes and mitochondria [8]. However, from a more recent de-
tailed analysis of the genes involved it was concluded that the
evidence for the involvement of glycosomes in fatty acid oxida-
tion is rather weak [9]. In fact, there have been hardly any
investigations on the oxidation of fatty acids by trypanosomes,
and where evidence is available for oxidation of fatty acids by
trypanosomes, the rates are minimal [10,11]. It is likely, but un-
known yet, that in T. brucei oxidation of fatty acids occurs for
very speciﬁc fatty acids only, or under certain conditions only,
or maybe even in other stages of the life cycle of this parasite
only, as it seems illogical that all genes are present yet would
never be used.3. Fatty acids: uptake from the host
As described above, fatty acids are not a signiﬁcant source of
energy for T. brucei bloodstream and procyclic forms. The
bloodstream forms rely exclusively on carbohydrates to produce
ATP, whereas the procyclic forms can use carbohydrates but
also amino acids, such as proline and threonine, for this purpose
[3–5]. This absence of the use of fatty acids as fuel implies thatT.
brucei needs fatty acids mainly for structural purposes, as com-
ponents of for instance phospholipids, sterol esters and lipid an-
chors for proteins and glycoconjugates. In principle, T. brucei
seems to have a choice between acquisition of these fatty acids
from the host, or to synthesize them de novo.
In accordance with their opportunistic way of living, para-
sites usually have very limited biosynthetic capacities. When-
ever possible they obtain substrates for the synthesis of their
structural elements from the host. More complex molecules
that the parasite cannot obtain directly from the host are syn-
thesized from these simpler building blocks. This occurs, of
course, also when the parasites uses structural elements that
are not present in the host, or only in too limited amounts.
Bloodstream form T. brucei indeed acquires most of its lipids
from the host. The majority of these are obtained from circu-
lating lipoprotein particles of the host and for their rapid
growth they depend on the presence in the culture media of
plasma lipoproteins [12]. Both major classes of serum lipopro-
teins, LDL and HDL, are primary sources of lipids, delivering
cholesterol esters, cholesterol and phospholipids to trypano-
somes [13]. Uptake occurs via endocytosis and most likely
exclusively via a clathrin-dependent mechanism [14]. This
endocytosis is restricted to a bulb-shaped invagination of the
plasma membrane known as the ﬂagellar pocket, which com-
prises just 5% of the cell surface and is not lined with the
micro-tubule network that encases the rest of the cell. It was
demonstrated that the acquisition by T. brucei bloodstream
forms of both the phospholipids of the amphipathic shell
and the cholesteryl esters in the core of LDL particles, relies
on receptor-mediated uptake and intracellular degradation of
LDL [15]. Bloodstream form T. brucei possess a lipoprotein
scavenger receptor, i.e. a receptor that can bind and mediate
the endocytosis of more than one ligand, here LDL, HDL
and TLF1 (trypanosome lytic factor, a subclass of HDL)
[16]. However, not all fatty acids are acquired via the uptake
of lipoprotein particles as bloodstream T. brucei also readily
incorporates exogenous oleate conjugated to albumin into cho-
lesteryl oleate [17]. Furthermore, bloodstream form T. bruceicontains phospholipase A2 activity and is able to liberate free
fatty acids from circulating lysophosphatidylcholine (lysoPC)
[18]. In this way extracellular myristoyl-lysoPC can be used
by bloodstream T. brucei as a source of myristate. The high
activity of this pathway in bloodstream forms, compared with
procyclic culture form trypanosomes, suggests that it plays a
role in the acquisition of fatty acids for synthesis of the mem-
brane anchor of the variant surface glycoprotein [18].4. Fatty acids: de novo biosynthesis
It was long thought that the bloodstream form of T. brucei
does not synthesize fatty acids de novo [19]. This posed a prob-
lem, however, when it was discovered that the 10 million copies
of the trypanosome variant surface glycoprotein (VSG), that
cover each single bloodstream form T. brucei parasite and en-
ables it to evade the host’s immune response, are attached to
the lipid bilayer of the plasma membrane of the parasite via a
glycosylphosphatidylinositol (GPI) anchor containing exclu-
sively twomyristatemolecules [20]. Obviously the parasites have
a tremendous requirement for this saturated fatty acid with 14
carbon atoms, as VSG is such an abundant protein (constituting
10% of total protein of the cell).Myristate is, however, relatively
rare in the blood of the host. Recently it was shown that blood-
stream form trypanosomes obtain part of themyristate required
for their VSG coat from the host, but that they also synthesize a
large part of the myristate de novo [21].
Interestingly, the procyclic form of T. brucei also has surface
coat proteins that are GPI anchored, yet in this stage the GPI
anchor does not contain myristate [22]. This form of the para-
site lives in the insect midgut and does not have a VSG coat,
but expresses a stagespeciﬁc surface glycoprotein that covers
its entire surface [23]. This glycoprotein is called procyclin
and during the diﬀerentiation process of the bloodstream
forms into the procyclic insect stage, the VSG coat is gradually
replaced by procyclins. Like VSGs these procyclins are also at-
tached to the plasma membrane via GPI, but in this case the
anchors do not consist of myristate, but of longer fatty acids
with chain lengths varying from 16 to 18 C-atoms [22].
Although the capacity of de novo fatty acid biosynthesis in
bloodstream T. brucei was only discovered recently, it is
known already for a long time that the cultured procyclic form
can produce fatty acids [24]. Using a cell-free system it was
shown that bloodstream form T. brucei synthesizes predomi-
nantly myristate and that this fatty acid was preferentially
incorporated into GPIs and not into other lipids [21]. In the
same study it was shown that a cell-free system obtained from
procyclic forms produces more hydrophobic species. Recent
studies using intact proliferating procyclic form T. brucei con-
ﬁrmed that this stage produces mainly fatty acids of 16 or 18
carbon atoms [6]. Although the diﬀerence in fatty acids used
for their GPI anchors could explain the need for the synthesis
of fatty acids of diﬀerent chain lengths, the mechanism which
results in this striking diﬀerence between bloodstream and pro-
cyclic forms of T. brucei in the de novo synthesis of fatty acids
was still an unresolved mystery till very recently (see below).
Fatty acid synthesis is a cyclic process and each round in
fatty acid synthesis starts with the formation of malonyl-
CoA from acetyl-CoA by acetyl-CoA carboxylase (ACC).
Interestingly, the putative gene for this trypanosomal ACC
suggests that this enzyme is similar to the multi-functional
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otic complex [19]. The rest of the machinery seems to be more
like the prokaryote-type system. From data derived from the
T. brucei genome project it was concluded that the production
of fatty acids by trypanosomes is mediated by a type II fatty
acid synthesis system [19]. Type II fatty acid biosynthesis is
performed by discrete proteins, each catalysing a single step
in the process. In type I fatty acid synthesis the reactions are
similar, but they are performed by a multi-domain polypeptide
that contains all the necessary catalytic activities and the acyl-
carrierprotein [25]. Type I fatty acid synthesis is present in the
cytosol of most higher eukaryotes. Type II fatty acid synthesis,
on the other hand, occurs in bacteria and mitochondria, as
well as in the chloroplasts of plants. The observation that T.
brucei possesses type II fatty acid synthesis indicates that this
process is a potential chemotherapeutic target and has stimu-
lated further investigations [19].
Recently it was discovered, however, that this type II fatty
acid synthesis, which is located inside the mitochondria of T.
brucei, produces fatty acids at low levels only [26]. It was
shown that T. brucei uses three microsomal elongases for the
synthesis of nearly all its fatty acids. Three elongases synthe-
size fatty acids in a stepwise manner, where the ﬁrst enzyme
converts C4–C10, the second one elongates C10–C14, and
elongase 3 extends preferentially C14–C18 [26]. Selective
down-regulation of this elongase 3 in the bloodstream stage ex-
plains the almost exclusive production of myristate, which is
required for the synthesis of the GPI anchors of the VSGs in
this stage of the life cycle.
Compared to the levels in plasma of the mammalian host,
trypanosomes contain higher levels of linoleic acid (18:2) and
polyunsaturated fatty acids, such as 22:5 and 22:6, and it was
already early suggested that trypanosomes can carry out chain
elongation and desaturation reactions to modify the fatty acids
they obtain from the host [10,27]. Analysis of the genome of T.
brucei revealed the presence of a plant-like fatty acid desaturase
[28] and after cloning and heterologous expression, a desatur-
ase of this parasite was recently characterized [29].5. Phospholipids: composition and biosynthesis
Phospholipids constitute the major proportion of total lipids
in African trypanosomes [30]. Both procyclic and bloodstream
form T. brucei contain phospholipids of all classes present in
mammalian cells, such as phosphatidylcholine (PC), phospha-
tidylethanolamine (PE), phosphatidylserine (PS), phosphati-
dylinositol (PI), phosphatidylglycerol (PG), cardiolipin and
sphingomyelin [31]. Trypanosomes do not obtain intact phos-
pholipids from their hosts, but instead synthesize their own
phospholipids using headgroups (such as choline, ethanol-
amine and inositol) acquired from the host, and fatty acids,
either de novo synthesized, or from the host (and then often
modiﬁed) (Fig. 1). Analysis of the fatty acid composition of
these lipids in whole T. brucei cells demonstrated that the fatty
acid composition of the phospholipids of the parasite diﬀers
during the life cycle, it diﬀers among the distinct phospholipid
classes, and it diﬀers from that of the host [30,31]. In general,
bloodstream form trypanosomes demonstrate less diversity in
phospholipid species compared to procyclic forms. Further-
more, compared to bloodstream forms, procyclic T. brucei
contain relatively high amounts of poly-unsaturated long-chain fatty acids, such as fatty acids with 22 carbon atoms
and ﬁve or six desaturations (22:5 and 22:6) [31]. Diﬀerences
in fatty acid species composition have strong eﬀects on the bio-
physical properties of the membrane, such as membrane ﬂuid-
ity and thickness. Hence, the increased amount in desaturated
fatty acids in procyclic cells compared to bloodstream forms is
likely to be an adaptation to the decrease in environmental
temperature in the ﬂy compared to that in the mammalian
blood vessel. However, the cellular functions of the observed
diﬀerences in phospholipid species composition are far from
understood, also because systematic information on the lipid
composition of distinct organelles is still lacking.
Several aspects of lipid metabolism in African trypanosomes
have been studied in detail and the completion of the T. brucei
genome has generated valuable information, as multiple T.
brucei genes were identiﬁed that are homologous to genes
encoding well characterized enzymes involved in phospholipid
metabolism [8]. The T. brucei genome contains homologues of
all genes necessary for de novo biosynthesis of all phospholipid
classes (F.R. Opperdoes, Personal communication). Similar to
higher eukaryotes, genes are present in T. brucei for de novo
biosynthesis of the phospholipids PC and PE via PA and
DAG (Kennedy pathway) and pulse-chase experiments using
radioactively-labelled ethanolamine demonstrated indeed sig-
niﬁcant activity of this Kennedy-pathway in bloodstream form
trypanosomes [32]. In addition, PE can also be synthesized by
trypanosomes from PS either via PS-decarboxylase or via the
exchange of serine-headgroup by ethanolamine [32,33]. In
contrast to mammals, PE does not function as a precursor
for PC-biosynthesis via methylation of PE into PC [32]. PS
can be synthesized from other phospholipids via base exchange
(Fig. 1). Similar to mammals, genes necessary for de novo bio-
synthesis of PI and PG via CDP-diacylglycerol are present in
trypanosomes. Recently, the enzyme PI-synthase has been
characterized and knock-out experiments demonstrated that
this enzyme is crucial for PI biosynthesis, and therefore, also
for GPIanchor biosynthesis [34].
Next to these de novo synthesis pathways, lyso-phospholip-
ids, phospholipids from which one acyl-chain has been re-
moved, are taken up from the environment by trypanosomes
after which these are acylated to phospholipids by acyl-trans-
ferases [18,35]. This pathway has been reported to be more
active in bloodstream from T. brucei compared to procyclic
forms [18], and PC synthesis in bloodstream forms using
lyso-PC exceeds that of de novo PC synthesis using exogenous
choline [36]. The acylation of lyso-phospholipids requires
coenzyme-A activated fatty acids, which can be synthesized
by four trypanosomal fatty acyl-CoA synthases, each with
their own fatty acid substrate speciﬁcity [37]. Remodelling of
acquired fatty acids also occurs at high rates in trypanosomat-
ids [10,35,38], which indicates that phospholipids in the try-
panosomal membranes require acyl chains distinct from
those acquired from the host. All together, these results show
that trypanosomes can synthesize phospholipids by multiple
pathways suggesting that their phospholipid metabolism is
very ﬂexible, which would allow trypanosomes to adapt their
lipid metabolism to the variable supply of distinct substrates
in their varying environments.
Trypanosomatids contain relatively large amounts of ether-
lipids, which contain either an O-alkyl or an O-alk-1-enyl bond
(in plasmalogens) at the sn-1 position of glycerol backbone.
All three initial and essential enzymes for ether-phospholipid
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transferase, alkyl-dihydroxy-acetonephosphate synthase and
alkyl-dihydroxy-acetonephosphate oxidoreductase have been
demonstrated in trypanosomatids at the genetic as well as at
the protein level [9,39,40]. In mammals these enzymes reside
in the matrix of peroxisomes and in trypanosomatids these en-
zymes are localised in peroxisome-like organelles called glyco-
somes [39]. Glycosomes resemble peroxisomes in many
aspects, such as import machinery and long-chain fatty acid
metabolism, but glycosomes diﬀer from peroxisomes as they
contain the ﬁrst seven glycolytic enzymes as well (see introduc-
tion) [3,41,42].
The T. brucei genome project also detected genes homolo-
gous to genes involved in phosphorylation of PI. Phosphory-
lated forms of PI, such as PIP2, are important substrates for
signal transduction, because speciﬁc phospholipases C can re-
lease phosphorylated inositides, such as IP3. However, the cel-
lular functions of phosphorylated PI metabolism have not
been resolved in T. brucei yet.
All together these results demonstrate that trypanosomes do
not acquire complete phospholipids from their host, but
instead synthesize their own phospholipids, including the
ether-linked species, from various substrates depending on
their supply in the environment of the parasite. When present,
exogenous lyso-phospholipids and fatty acids are preferred as
building blocks for the assembly of phospholipids. Alterna-
tively, phospholipids can be synthesized by T. brucei from de
novo synthesized fatty acids, glycolytic triose-phosphate inter-
mediates (e.g. glycerol-3-phosphate) and phospholipid head-
group moieties (e.g. choline, ethanolamine), which are usually
obtained from the host.6. Mevalonate pathway
The mevalonate pathways starts with the key enzymes, 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) synthaseand HMG-CoA reductase, which convert acetoacetyl-CoA
and acetyl-CoA into mevalonate that is subsequently used
for the synthesis of isoprenoid groups (Fig. 1). Subcellular
localisation of HMG-CoA reductase seems to be diﬀerent from
that in the mammalian host, where it is located in the smooth
endoplasmic reticulum. In T. brucei HMG-CoA reductase
activity was shown to be a soluble enzyme present in the mito-
chondrial matrix with some additional membrane-associated
activity in glycosomes and possibly in the endoplasmic reticu-
lum [9,43]. The produced isoprenoid residues are used for the
synthesis of a divers group of vital lipids comprising among
others sterols, quinones, isopentenyladenine and dolichol-
and farnesyl moieties for protein modiﬁcations. In trypano-
somes genes have been identiﬁed that encode homologues of
most enzymes of the mevalonate pathway [8]. In addition,
pulse chase experiments using radioactively-labelled mevalo-
nate demonstrated the presence in trypanosomes of de novo
synthesis of isoprenoid residues for protein-prenylation, for
dolichol with 11 and 12 isoprenoid residues, for ubiquinone
with nine isoprenoid residues and for synthesis of ergosterol,
a C28 sterol [15,44,45]. Hence, trypanosomes have an active
isoprenoid metabolism, which diﬀers in several aspects from
mammals (see below).
African trypanosomes do not synthesize cholesterol de novo,
but instead synthesize ergosterol and other 24-alkylated ster-
ols, similar to plants and fungi [25]. However, when cholesterol
is present in their environment it is incorporated by the para-
site without further metabolism [44]. Trypanosomes acquire
cholesterol from the host via receptor mediated endocytosis
of low density lipoproteins (LDL) followed by lysosomal deg-
radation [15,17]. Procyclic trypanosomes are ﬂexible with re-
spect to the source of sterols, as these cells adjust their de
novo ergosterol biosynthesis to the external supply of choles-
terol [15]. However, bloodstream form trypanosomes, which
contain predominantly cholesterol, are dependent on sterol up-
take from the host, as lipoproteins were demonstrated to be an
essential source of cholesterol for these cells [17]. Apparently,
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amounts of ergosterol, and therefore, interference with low
density lipoproteins has been postulated as a target for anti-
trypanosomal drug development [46].
Ergosterol, a sterol common in plants and fungi, diﬀers
structurally from cholesterol both in number and position of
desaturations and methylations. Hence, ergosterol biosynthesis
in trypanosomatids diﬀers from the biosynthesis of cholesterol
in mammals and shares most characteristics with that in fungi
[25]. After synthesis of the core sterol structure, diﬀerent mod-
iﬁcations have to occur in trypanosomatids compared to mam-
mals. The exact order of all the modiﬁcations made to the core
sterol structure has not been determined in T. brucei, but de-
tailed studies on sterol biosynthesis have been performed on
the trypanosomatid Leishmania (for a recent review see [25]).
In contrast to cholesterol synthesis in mammals, ergosterol
synthesis in trypanosomatids requires methylations by the en-
zyme sterol methyl transferase, which does not have a counter-
part in mammals [47]. Although the sterol methyl transferase
from T. brucei demonstrated signiﬁcant similarity at the pri-
mary amino acid sequence level to those of plants and yeast,
recent biochemical characterization of the T. brucei sterol
methyl transferase demonstrated unique catalytic properties
in respect to substrate speciﬁcity, which suggests that sterol
biosynthesis in trypanosomatids also diﬀers from that in fungi
[48]. Inhibitors of sterol methyl transferases have been tested
as antitrypanosomal drugs, and surprisingly azasterols were
shown to be active also against bloodstream form trypano-
somes [49]. It was suggested that these bloodstream forms
either synthesize minor, but essential, amounts of ergosterol
or that sterol precursors taken up from host are methylated
by sterol methyl transferases [49].
Ubiquinone, an essential transporter in the electron-trans-
port chain in aerobic functioning mitochondria, is another
product of the mevalonate pathway in most eukaryotes [50].
In higher eukaryotes, ubiquinone consists of a benzoquinone
to which a hydrophobic chain of 7–10 isoprenoid residues is at-
tached. Trypanosomes contain all genes needed for the de
novo synthesis of ubiquinone [8], and ubiquinone is thought
to be synthesized de novo in trypanosomatids [51], because
the hydrophobic isoprenoid-tail is synthesized de novo from
mevalonate [45].
Relatively short isoprenoid-chains, such as farnesyl and
geranylgeranyl that contain 15 and 20 carbon atoms, respec-
tively, can be covalently linked to proteins by a process known
as protein prenylation. The hydrophobic isoprenoid tail that is
then attached to the protein, facilitates crucial membrane
association and protein–protein interactions. Protein prenyl-
ation has been studied in great detail in mammals, because
prenylation of small GTPases is an important target for the
development of novel anti-cancer chemotherapeutics [52].
Protein prenylation of small GTPases also occurs in African
trypanosomes, and involves the enzymes protein farnesyltrans-
ferase and two types of protein geranylgeranyltransferase
(types 1 and 2). These enzymes in T. brucei have been studied
in great detail because the already developed large number of
inhibitors for their mammalian counterparts can be exploited
to identify inhibitors speciﬁc for prenylation in trypanosomes.
Protein prenylation in trypanosomes as well as the ‘piggy-
back medicinal chemistry’ will not be described in this
review, because excellent reviews have recently been published
[53,54].7. Lipid metabolism as drug target
Although trypanosomatids are apparently very ﬂexible in
most aspects of their lipid metabolism (see above), a number
of enzymes in divers pathways have proven to be valid targets
for the development of novel chemotherapeutics. These targets
not only comprise parasite speciﬁc enzymes that catalyse essen-
tial reactions in lipid biosynthesis pathways that are absent or
distinct from that in the host (such as biosynthesis of fatty
acids and GPI-anchors), but they also comprise enzymes cata-
lysing essential reactions in pathways of lipid metabolism that
are similar to that of the host. Of course, the development of
speciﬁc inhibitors that kill the parasite without aﬀecting the
host, is in principle more diﬃcult when homologues of the tar-
get enzyme in the parasite also exist in the host. However,
when inhibitors for an essential enzyme have been generated,
compounds can be detected that speciﬁcally inhibit the para-
sitic enzyme, as was proven for the protein prenylation en-
zymes in T. brucei [54,55].
Lipid metabolism in trypanosomes comprises at least two
pathways, ergosterol synthesis and type II fatty acid biosynthe-
sis, that are also present in fungi and apicomplexa, but absent
in mammals. A number of well-known inhibitors of these en-
zymes in fungi appeared to be also eﬀective against T. brucei,
as thiolactomycin (and its derivatives) was shown to inhibit
type II fatty acid biosynthesis [56]. Hence, drugs inhibiting
pathogenspeciﬁc enzymes of which homologues are present
in T. brucei, are promising lead compounds for novel anti-try-
panosomal drugs.
Although alkyl-phosphocholines, a group of lyso-phospho-
lipid analogues, were originally developed as anti-cancer
drugs, these compounds appeared to be eﬀective drugs against
the trypanosomatids T. cruzi and especially Leishmania spp.
[57]. Their structure suggests that these drugs interfere with
lipid metabolism or function, but the molecular target or
mechanism has not been identiﬁed yet. No alkyl-phosphocho-
line structure speciﬁcally eﬀective against T. brucei has been
identiﬁed yet, but hexadecylphosphocholine (miltefosine) has
recently been introduced as an oral treatment for leishmaniasis
[58]. Therefore, interference with lipid metabolism in parasitic
pathogens can be exploited successfully for the generation of
novel drugs to combat clinically important diseases.
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